U.S. Drug Manufacturers Stock News
Categories
- All
- Editor's Picks
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
GuruFocus News Drug Manufacturers
Merck & Co Inc (MRK) Q3 2024 Earnings Call Highlights: Strong Oncology and Animal Health Drive Revenue Growth
Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, setting a positive outlook for future quarters. Nov 01, 2024
GuruFocus News Drug Manufacturers
Organon & Co (OGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
Organon & Co (OGN) reports robust performance with a 5% revenue increase and strategic moves in dermatology, despite facing pricing pressures in key markets. Nov 01, 2024
GuruFocus News Drug Manufacturers
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Investments Propel Future Prospects
With a 20% increase in growth portfolio revenue and strategic cost savings, Bristol-Myers Squibb Co (BMY) raises its full-year guidance amidst competitive challenges. Nov 01, 2024